Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease

Hormone and Metabolic Research

Volumn 43, Issue 3, 2011, Pages 194-199

  Leite, A C ^a   Pedro, A B P ^a   Romaldini, J H ^a  

^a INSTITUTO DE ASSISTÊNCIA MÉDICA AO SERVIDOR PÚBLICO ESTADUAL   (Brazil)

Author keywords

antibodies to thyroperoxidase; autoantibodies; autoimmunity; CXC chemokines; CXL10; hyperthyroidism; TSH receptor antibodies

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; IODINE 131; LIOTHYRONINE; THIAMAZOLE; THYROGLOBULIN; THYROID PEROXIDASE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN RECEPTOR; THYROXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; EUTHYROIDISM; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MALE; PRIORITY JOURNAL; RELAPSE; SINGLE DRUG DOSE; THYROGLOBULIN BLOOD LEVEL; THYROID FUNCTION; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTITHYROID AGENTS; CASE-CONTROL STUDIES; CHEMOKINE CXCL10; FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; METHIMAZOLE; MIDDLE AGED;

EID: 79952484210     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1271620     Document Type: Article

References (51)

1. Weetman AP. Graves' disease. N Engl J Med 2000 343 1236-1248
2. Davies TF, Greenberg D, Tomer Y. The genetics of the autoimmune thyroid diseases. Ann Endocrinol (Paris) 2003 64 28-30 (Pubitemid 36433325)
3. Liu C, Papewalis C, Domberg J, Scherbaum WA, Schott M. Chemokines and autoimmune thyroid diseases. Horm Metab Res 2008 40 361-368 (Pubitemid 351967125)
4. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994 15 788-830
5. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000 85 776-780 (Pubitemid 32273668)
6. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M. Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease. Am J Pathol 2002 161 195-206 (Pubitemid 34760785)
7. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini E, Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004 89 5496-5499 (Pubitemid 39518431)
8. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, Serio M. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005 152 171-177 (Pubitemid 40309561)
9. Garcia-Lopez MA, Sancho D, Sanchez-Madrid F, Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J Clin Endocrinol Metab 2001 86 5008-5016 (Pubitemid 33020557)
10. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2003 59 207-213 (Pubitemid 36918657)
11. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000 18 217-242
12. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000 12 121-127 (Pubitemid 30398626)
13. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994 343 831-836 (Pubitemid 24147515)
14. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998 392 565-568 (Pubitemid 28207705)
15. Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998 338 436-445 (Pubitemid 28135672)
16. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997 349 490-495 (Pubitemid 27077839)
17. Rotondi M, Minelli R, Magri F, Leporati P, Romagnani P, Baroni MC, Delsignore R, Serio M, Chiovato L. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis. Eur J Endocrinol 2007 156 409-414 (Pubitemid 46679458)
18. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007 97 714-721 (Pubitemid 46804314)
19. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001 107 53-63 (Pubitemid 32047414)
20. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004 25 201-209 (Pubitemid 38372168)
21. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001 410 50-56 (Pubitemid 32225831)
22. Corona G, Biagini C, Rotondi M, Bonamano A, Cremonini N, Petrone L, Conforti B, Forti G, Serio M. Correlation between, clinical, biochemical, color Doppler ultrasound thyroid parameters, and CXCL-10 in autoimmune thyroid diseases. Endocr J 2008 55 345-350 (Pubitemid 351670961)
23. Kimura H, Caturegli P. Chemokine orchestration of autoimmune thyroiditis. Thyroid 2007 17 1005-1011 (Pubitemid 350080348)
24. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007 28 492-520 (Pubitemid 47236335)
25. Rotondi M, Lazzeri E, Romagnani P, Serio M. Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field. J Endocrinol Invest 2003 26 177-180 (Pubitemid 36503068)
26. Shigihara T, Oikawa Y, Kanazawa Y, Okubo Y, Narumi S, Saruta T, Shimada A. Significance of serum CXCL10/IP-10 level in type 1 diabetes. J Autoimmun 2006 26 66-71 (Pubitemid 43138895)
27. Rotondi M, Falorni A, de Bellis A, Laureti S, Ferruzzi P, Romagnani P, Buonamano A, Lazzeri E, Crescioli C, Mannelli M, Santeusanio F, Bellastella A, Serio M. Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab 2005 90 2357-2363 (Pubitemid 40586285)
28. Weetman AP, Bennett GL, Wong WL. Thyroid follicular cells produce interleukin-8. J Clin Endocrinol Metab 1992 75 328-330
29. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006 154 651-658 (Pubitemid 43810850)
30. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin Endocrinol (Oxf) 2006 64 189-195
31. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006 91 614-620 (Pubitemid 43236933)
32. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 2006 93 1226-1231 (Pubitemid 44547021)
33. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 2007 92 1485-1490 (Pubitemid 46556429)
34. Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC, Schott M. Circulating chemokines in patients with autoimmune thyroid diseases. Horm Metab Res 2008 40 416-421 (Pubitemid 351967134)
35. Sakai H, Togawa Y, Fukuda G, Ito R, Miwa T, Odawara M. Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves' disease in long-term remission. Thyroid 2010 20 341-342
36. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000 164 6503-6508 (Pubitemid 30408835)
37. Nygaard B, Jarlov AE, Kristensen LO, Faber J. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter. Horm Metab Res 2000 32 283-287 (Pubitemid 30646894)
38. Lazarus JH, Clarke S. Use of radioiodine in the management of hyperthyroidism in the UK: development of guidelines. Thyroid 1997 7 229-231 (Pubitemid 27190587)
39. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003 88 978-983 (Pubitemid 36337742)
40. Blomgren H, Petrini B, Wasserman J, Schnell PO, Lundell G. Changes of the blood lymphocyte population following 131I treatment for nodular goiter. Int J Radiat Oncol Biol Phys 1987 13 209-215 (Pubitemid 17033833)
41. Teng WP, Stark R, Munro AJ, Young SM, Borysiewicz LK, Weetman AP. Peripheral blood T cell activation after radioiodine treatment for Graves' disease. Acta Endocrinol (Copenh) 1990 122 233-240 (Pubitemid 20068298)
42. Laurberg P. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 2006 155 783-786 (Pubitemid 46040614)
43. Pedro AB, Romaldini JH, Takei K. Changes of Serum Cytokines in Hyperthyroid Graves' Disease Patients at Diagnosis and during Methimazole Treatment. Neuroimmunomodulation 2010 18 45-51
44. Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine - a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996 81 2986-2993
45. Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, Mazzinghi B, Francalanci M, Pezzatini A, Perigli G, Vannelli GB, Annunziato F, Serio M. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol 2007 195 145-155 (Pubitemid 350056008)
46. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008 158 69-75 (Pubitemid 351211042)
47. Atkinson S, McGregor AM, Kendall-Taylor P, Peterson MM, Smith BR. Effect of radioiodine on stimulatory activity of Graves' immunoglobulins. Clin Endocrinol (Oxf) 1982 16 537-543 (Pubitemid 12111424)
48. Teng CS, Yeung RT, Khoo RK, Alagaratnam TT. A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves' disease treated by subtotal thyroidectomy or radioactive iodine. J Clin Endocrinol Metab 1980 50 1005-1010 (Pubitemid 10007666)
49. Inukai Y, Momobayashi A, Sugawara N, Aso Y. Changes in expression of T-helper (Th) 1- and Th2-associated chemokine receptors on peripheral blood lymphocytes and plasma concentrations of their ligands, interferon-inducible protein-10 and thymus and activation-regulated chemokine, after antithyroid drug administration in hyperthyroid patients with Graves' disease. Eur J Endocrinol 2007 156 623-630 (Pubitemid 46952531)
50. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 1980 303 302-307 (Pubitemid 10040018)
51. Cooper DS. Antithyroid drugs. N Engl J Med 2005 352 905-917 (Pubitemid 40300299)